News Takeda Pharmaceutical Company Limited OTC Markets

Equities

TKPHF

JP3463000004

Delayed OTC Markets Other stock markets 07:00:22 20/06/2024 pm IST			5-day change	1st Jan Change
24.48 ^USD	-4.00%		-8.76%	-14.79%

08:50am	Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	MT
07:47am	Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older	05:31pm	AQ
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	12:20pm	MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	11:17am	RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	09:29am	MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	08:58am	CI
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	19/06	AQ
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat	18/06	AQ
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	18/06	MT
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting	18/06	BU
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	18/06	CI
Takeda's Soticlestat Shows Promising Secondary Outcomes in Phase 3 Studies for Dravet and Lennox-Gastaut Syndromes	18/06	MT
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback	17/06	DJ
Sector Update: Health Care Stocks Decline Premarket Monday	17/06	MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell	17/06	MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	17/06	MT
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	17/06	MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies	17/06	DJ
Takeda's seizure drug fails to meet main goal in late-stage studies	17/06	RE
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	17/06	CI
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K	17/06	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Takeda Pharmaceutical Company Limited OTC Markets

Equities

TKPHF

JP3463000004

Summary

Filters